Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-016-2334-x ◽

2017 ◽

Vol 143 (4) ◽

pp. 727-734 ◽

Cited By ~ 16

Author(s):

Jian-Xian Lin ◽

Qing-Feng Chen ◽

Chao-Hui Zheng ◽

Ping Li ◽

Jian-Wei Xie ◽

...

Keyword(s):

High Risk ◽

Imatinib Mesylate ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Journal of Surgical Oncology ◽

10.1002/jso.21160 ◽

2009 ◽

Vol 99 (1) ◽

pp. 42-47 ◽

Cited By ~ 247

Author(s):

Burton L. Eisenberg ◽

Jonathan Harris ◽

Charles D. Blanke ◽

George D. Demetri ◽

Michael C. Heinrich ◽

...

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Early Results

Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.9009 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 9009-9009 ◽

Cited By ~ 21

Author(s):

R. P. Dematteo ◽

C. R. Antonescu ◽

V. Chadaram ◽

Y. N. You ◽

L. McCall ◽

...

Keyword(s):

High Risk ◽

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Complete Resection ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

The U.S

Faculty Opinions recommendation of Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1147293.604446 ◽

2009 ◽

Author(s):

Florence Duffaud

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Early Results

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

BMC Cancer ◽

10.1186/1471-2407-10-199 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 17

Author(s):

Jiang Zhu ◽

Yu Yang ◽

Lin Zhou ◽

Ming Jiang ◽

Mei Hou

Keyword(s):

Liver Metastasis ◽

Imatinib Mesylate ◽

Stromal Tumor ◽

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

Annals of Surgical Oncology ◽

10.1245/s10434-011-2190-5 ◽

2011 ◽

Vol 19 (4) ◽

pp. 1074-1080 ◽

Cited By ~ 111

Author(s):

Dian Wang ◽

Qiang Zhang ◽

Charles D. Blanke ◽

George D. Demetri ◽

Michael C. Heinrich ◽

...

Keyword(s):

Radiation Therapy ◽

Gastrointestinal Stromal Tumors ◽

Phase Ii Trial ◽

Radiation Therapy Oncology Group ◽

Oncology Group ◽

Adjuvant Imatinib ◽

Stromal Tumors ◽

Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604)

Annals of Oncology ◽

10.1093/annonc/mdy283.124 ◽

2018 ◽

Vol 29 ◽

pp. viii325

Author(s):

R.A. Huddart ◽

F. Cafferty ◽

J. White ◽

J. Shamash ◽

I.M. Hennig ◽

...

Keyword(s):

Germ Cell ◽

Induction Chemotherapy ◽

Phase Ii ◽

Poor Prognosis ◽

Phase Ii Trial ◽

Germ Cell Tumours ◽

Randomized Phase Ii ◽

Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): A case-control study from GEIS

Annals of Oncology ◽

10.1093/annonc/mdx387.037 ◽

2017 ◽

Vol 28 ◽

pp. v534

Author(s):

C. Serrano ◽

A. Lopez Pousa ◽

I. Pajares ◽

C. Valverde Morales ◽

J. Duran ◽

...

Keyword(s):

Case Control Study ◽

Case Control ◽

Stromal Tumor ◽

Clinicopathologic Features ◽

Durable Response ◽

Long Term Follow Up ◽

Control Study

Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4507 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4507-4507 ◽

Cited By ~ 1

Author(s):

A. Lorch ◽

A. Kleinhans ◽

A. Kramar ◽

J. T. Hartmann ◽

C. Bokemeyer ◽

...

Keyword(s):

Germ Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

Germ Cell Tumors ◽

High Dose Chemotherapy ◽

High Dose ◽

Randomized Phase Ii ◽

Sa1543 Long Term Follow-Up Result of Endoscopic Resection of Gastric Gastrointestinal Stromal Tumor

Gastrointestinal Endoscopy ◽

10.1016/j.gie.2015.03.316 ◽

2015 ◽

Vol 81 (5) ◽

pp. AB254-AB255

Author(s):

Min Jae Yang ◽

Sun Gyo Lim ◽

Sung Jae Shin ◽

Kee Myung Lee

Keyword(s):

Endoscopic Resection ◽

Stromal Tumor ◽